Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide versus placebo in high-risk nonmetastatic castration-resistant prostate cancer
NL-OMON59878Phase 3Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Mar 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Apalutamide with Placebo (2 arms). Primary endpoint: Metastasis-Free Survival. Started Mar 2014; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON59878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59878.